RxDoctor Payments Data

Oana Petcu, MD

Internal Medicine · Baton Rouge, LANPI 1326086083

Payments from drug & device makers

$716in general payments, 2019–2025

Across 35 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$214
  • E.r. Squibb & Sons, L.L.C.$162
  • Johnson & Johnson$133
  • Acadia Pharmaceuticals Inc$105
  • Pfizer$67
  • CMP Pharma, Inc.$19
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$63188%
  • Education$8512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$214
E.r. Squibb & Sons, L.L.C.10$162
Johnson & Johnson6$133
Acadia Pharmaceuticals Inc5$105
Pfizer3$67
CMP Pharma, Inc.1$19
Merck1$16

How this compares

$716 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$164,738
Medicare patients
548
Services billed
1,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate25$61,641
EliquisApixaban173$51,496
JardianceEmpagliflozin64$19,449
LinzessLinaclotide33$18,953
XareltoRivaroxaban66$18,845
TrulicityDulaglutide18$18,474
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,043
EntrestoSacubitril/Valsartan57$14,976
RestasisCyclosporine16$10,945
NuedextaDextromethorphan Hbr/Quinidine12$9,395
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc92$9,284
Breo ElliptaFluticasone/Vilanterol20$8,626
MyrbetriqMirabegron36$8,282
TradjentaLinagliptin27$7,129
Leucovorin Calcium12$7,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$105$61,64125 claims
PfizerEliquis$67$51,496173 claims
Johnson & JohnsonXarelto$133$18,84566 claims
AstraZenecaFarxiga$214$5,50819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →